Argon reduces microglial activation and inflammatory cytokine expression in retinal ischemia/reperfusion injury

Ulrich Goebel, Stefanie Scheid, Sashko Spassov, Nils Schallner, Jakob Wollborn, Hartmut Buerkle, Felix Ulbrich

Abstract
We previously found that argon exerts its neuroprotective effect in part by inhibition of the toll-like receptors (TLR) 2 and 4. The downstream transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NF-kB) are also affected by argon and may play a role in neuroprotection. It also has been demonstrated that argon treatment could mitigate brain damage, reduce excessive microglial activation, and subsequently attenuate brain inflammation. Despite intensive research, the further exact mechanism remains unclear. In this study, human neuroblastoma cells were damaged in vitro with rotenone over a period of 4 hours (to mimic cerebral ischemia and reperfusion damage), followed by a 2-hour post-conditioning with argon (75%). In a separate in vivo experiment, retinal ischemia/reperfusion injury was induced in rats by increasing intraocular pressure for 1 hour. Upon reperfusion, argon was administered by inhalation for 2 hours. Argon reduced the binding of the transcription factors signal transducer and activator of transcription 3, nuclear factor kappa B, activator protein 1, and nuclear factor erythroid 2-related factor 2, which are involved in regulation of neuronal damage. Flow cytometry analysis showed that argon downregulated the Fas ligand. Some transcription factors were regulated by toll-like receptors; therefore, their effects could be eliminated, at least in part, by the TLR2 and TLR4 inhibitor oxidized phospholipid 1-palmitoyl-2- arachidonoyl-sn-glycero-3-phosphorylcholine (OxPAPC). Argon treatment reduced microglial activation after retinal ischemia/reperfusion injury. Subsequent quantitative polymerase chain reaction analysis revealed a reduction in the pro-inflammatory cytokines interleukin (IL-1α), IL-1β, IL-6, tumor necrosis factor α, and inducible nitric oxide synthase. Our results suggest that argon reduced the extent of inflammation in retinal neurons after ischemia/reperfusion injury by suppression of transcription factors crucial for microglial activation. Argon has no known side effects or narcotic properties; therefore, therapeutic use of this noble gas appears ideal for treatment of patients with neuronal damage in retinal ischemia/reperfusion injury. The animal experiments were approved by the Commission for Animal Care of the University of Freiburg (approval No. 35-9185.81/G14-122) on October 19, 2012.

Key Words: argon; ischemia/reperfusion injury; microglia; neuroinflammation; neuroprotection; noble gas; SH-SYSY; toll-like receptor; transcription factor

Introduction
Damage due to cerebral ischemia and reperfusion damage can destroy nerve tissues, leading to loss of function and increased mortality in affected patients. Anesthesia or surgery can reduce the blood supply, with resulting severe impairments that can manifest as delirium, cognitive dysfunction, or even stroke (Wesselink et al., 2018). At the cellular level, inflammatory and apoptotic processes play a major role in the deterioration of neurons (Ahmad et al., 2014). Neuronal cells have only a limited potential for regeneration, making cerebral ischemia and reperfusion injuries a major cause of morbidity and mortality (Ng et al., 2011). At present, no measures are available to counteract these degenerative processes.

In recent decades, a large number of drugs have been investigated for their potential neuroprotective effects against cerebral ischemia/reperfusion injury, predominantly in preclinical analyses, but most have had disappointing results. One exception is the noble gas argon, which has shown mostly positive results in terms of neuroprotection (Ulbrich et al., 2014, 2015a; Moretti et al., 2015). The protective effect of argon on neuronal tissue has been demonstrated in various ex vivo and in vivo studies (Soldatov et al., 1998; Loetscher et
al., 2009; Ryang et al., 2011; David et al., 2012; Fahlenkamp et al., 2012; Brucken et al., 2014; Ulbrich et al., 2014, 2015a). However, the molecular mechanism of action of argon has not been established.

We have demonstrated that argon has an in vivo anti-apoptotic effect (Ulbrich et al., 2014, 2015a, 2016). After ischemia/reperfusion injury of the retina, argon significantly reduced the death of retinal ganglion cells (Ulbrich et al., 2014). In addition, argon treatment activated extracellular regulated kinase 1/2 (ERK1/2), resulting in decreased expression of heme oxygenase-1 (Ulbrich et al., 2015a). Zhuang et al. (2012) also showed an effect of argon on the anti-apoptotic signaling pathway in a neonatal asphyxia model of the rat in the form of increases in B-cell lymphoma-2/Xl (Bcl-2/Bcl-xL) levels and decreases in Bcl-2-associated x protein levels in brain tissue (Zhuang et al., 2012). Fahlenkamp et al. (2012) conducted an in vitro investigation of the molecular mechanism by examining the influence of argon on primary neuronal and astroglial cell culture as well as on the microglial cell line BV-2. They found that argon treatment increased the phosphorylation of ERK1/2, and they reported, for the first time, an anti-inflammatory effect of argon via modulation of the expression of the pro-inflammatory cytokine IL-1β.

In a previous study, we exposed human neuroblastoma cells to argon following damage by rotenone (Ulbrich et al., 2014, 2015b). We found that argon exerts its neuroprotective effect, in part by inhibition of the toll-like receptors (TLR2) and TLR4. The downstream transcription factors signal transducer and activator of transcription 3 (STAT3) and nuclear factor kappa B (NF-kB) are also affected by argon and may play a role in neuroprotection (Przanowski et al., 2014; Ulbrich et al., 2014; Mouihate and Mehdawi, 2016). In cerebral injuries, the neuroprotective effect of argon appears to involve microglia, which are the resident immune cells of the central nervous system. Changes in microglial morphology and function are related to signaling molecules that are released in response to injury stimuli, such as stroke. For example, microglia aid in the elimination of dead neuronal cells and in the restoration of the delicate milieu within the central nervous system. However, excessive activation of microglia by damage-associated molecular patterns after an injury such as stroke can lead to the production of large quantities of pro-inflammatory cytokines by microglia, with negative effects on neuronal cells and neurogenesis (Xiong et al., 2016).

Recently, Liu et al. (2019) demonstrated that argon treatment could mitigate brain damage, reduce excessive microglial activation, and subsequently attenuate brain inflammation. We therefore hypothesized that argon might exert its neuroprotective effects in vitro and in vivo by modulating TLR downstream transcription factors, such as NF-kB, STAT3, activator protein 1 (AP-1), and nuclear factor erythroid 2-related factor 2 (Nrf-2), thereby altering microglial activation and suppressing inflammatory cytokine release.

**Materials and Methods**

**Reagents**

Rotenone was diluted in dimethyl sulfoxide to a concentration that would not exceed 0.5% in the cell culture medium. Argon was obtained as a mixture of argon (75%), oxygen (2%), and CO₂ (the balance was nitrogen) from Air Liquide (Kornwestheim, Germany). The TLR2 and TLR4 inhibitor OxpAPC (Cat# l-oxpp1), rotenone, and dimethyl sulfoxide were supplied by Sigma-Aldrich (St. Louis, MO, USA).

**Cell culture and treatments**

The cells of a neuroblastoma cell line (SH-SY5Y; Cat# CRL-2266, ATCC, Middlesex, UK) were cultured in a humidified 5% CO₂ environment at a temperature of 37°C in Dulbecco’s modified Eagle’s medium (DMEM/F12; Gibco ThermoFisher, Darmstadt, Germany) containing 1% penicillin/retomycin and 10% fetal calf serum. The cells were grown to 80% confluence and then 1.5 × 10⁵ cells were seeded in each well of a 6-well culture plate. After 48 hours of culture, the medium was changed to one containing 1% fetal calf serum to ensure that rotenone would not be inactivated by protein binding. The cells were treated with rotenone (20 µM) for 4 hours and then immediately exposed for 2 hours either to room air or to the 75% argon gas mixture in a hermetically sealed box. In TLR2 and TLR4 inhibition experiments, OxpAPC (30 µg/mL) was administered 60 minutes before the rotenone treatment. In all experiments, the cells were harvested immediately after the argon exposure for further analysis.

**Transcription factor-binding enzyme-linked immunosorbent assay**

The DNA binding activity of transcription factors STAT3, NF-kB, Nrf-2, and AP-1 family was determined by DNA binding ELISA according to the manufacturer’s instructions (STAT3: Cat# 45196, NF-kB: Cat# 40096, Nrf-2: Cat# 50296; AP-1 family: Cat# 44296 TransAM® Kit, ActiveMotif, Rixensart, Belgium). Neuroblastoma cells were seeded in 100 mm dishes and incubated until sufficient colonization was achieved. The cells were washed with ice-cold PBS, scraped from the dish surface, centrifuged, and incubated with a hypotonic buffer. Nonidet P-40 was added and the cell lysis was checked under a microscope. After centrifugation and removal of the supernatant, a lysate buffer was added. The protein content of the lysates was determined by the Bradford method (Bradford, 1976). Samples containing 10 µg protein were then incubated with the primary antibodies for 1 hour, and the DNA binding activity of the transcription factors was analyzed by measuring the optical density at 450 nm on a microplate reader (Tecan®, Männedorf, Switzerland).

**Flow cytometry of the Fas ligand**

The cells were washed several times with cold phosphate-buffered saline and then trypsinized and resuspended in 100 µL binding buffer. Staining was initiated with a fluorescein isothiocyanate conjugated anti-Fas ligand (FasL) antibody (Abcam, Cambridge, UK, Cat# ab10511; 1:40) and the cells were incubated for 15 minutes at room temperature. A 400 µL volume of binding buffer was then added and flow cytometry was conducted using an acoustic focusing cytometer (Attune®, Life Technologies, Darmstadt, Germany). Background fluorescence was determined by compensation and gate setting; unstained cells were used as negative controls.

**Animals**

Adult male and female Sprague-Dawley rats (male-to-female ratio 1:1, 280–350 g body weight; Charles River, Sulzfeld, Germany) were housed in a 12-hour light/12-hour dark cycle and fed ad libitum with a standard diet. All procedures performed on the animals were in accordance with the The state of California for the use of animals in research and were approved by the Commission for Animal Care of the University of Freiburg (approval No. 35-9185.81/G14-122) on October 19, 2012. All interventions were performed as described previously (Ulbrich et al., 2014, 2015b). Animals were randomized to three groups: I ischemia/reperfusion (n = 6), II ischemia/reperfusion+argon (n = 6), III ischemia/reperfusion+argon+OxpAPC (n = 6).

The number of animals used for molecular analysis was n = 6 per group. The number of animals used for immunoperoxidase labeling was n = 6 per group. Enucleation was performed after 24 hours.

**Retinal ischemia/reperfusion injury and argon treatment**

The rats were subjected to intraperitoneal anesthesia...
Ionized calcium binding adaptor molecule 1 (Iba-1) is a microglial/macrophage-specific calcium-binding protein. Iba-1 expressing cells in the retina were identified by immunohistochemistry. The rat eyes were enucleated (n = 6 per group) 24 hours after ischemia/reperfusion injury. The retinal tissue was removed and placed as a whole mount preparation in ice cold Hank’s balanced saline solution. The retinas were carefully transferred to a nitrocellulose membrane with the ganglion cell layer on top. The vitreous body was then removed and the specimens were fixed in 4% paraformaldehyde for 1 hour. Immunolabeling was performed according to standardized protocols (Trivino et al., 2002; Rojas et al., 2014) with mouse monoclonal antibody against Iba-1 (Cat# ab15690; dilution 1:150; Abcam). Conjugation of the primary antibody with the corresponding secondary antibodies was shown as follows. A green fluorescence was generated with Alexa Fluor 488 (goat anti-mouse, dilution 1:1000; Cat# 115-545-003, Jackson ImmunoResearch Europe, Cambridgeshire, UK). The nuclei of cells in the retina were stained with 4',6-diamidino-2-phenylindole-dihydrochloride hydrate (DAPI, Sigma, Taufkirchen, Germany). The preparations were covered with embedding medium (Mowiol; Calbiochem, San Diego, CA, USA) and stored at 4°C.

Analysis of microglia

Three-dimensional confocal laser scanning microscopy overview and close-up images were obtained with a LSM 510 device (Carl Zeiss, Jena, Germany) at 20× and 40× magnification, respectively. Z-stack images were deconvoluted using HuygensEssential 1605sp5 software (SVI, Hilversum, The Netherlands). For representative purposes, all images from each Z-stack were either focal plane merged (overview images) or 3D reconstructed (close-up images) using Imaris 8.3.0 image analysis software (Bitplane, Zurich, Switzerland).

Quantification and histogram analysis of immunostained images were performed using the ImageJ open source software (ImageJ, Version 2.00-rc-44/1.50e, https://imagej.nih.gov/ij/plugins/fraclac/FLHelp/Introduction.htm). Microglial morphology in relation to the cell shape was determined by quantifying the density of branch points (Morrison et al., 2017) using the FracLac plug-in from ImageJ. This generates a “convex hull,” where each microglia is surrounded by a polygon and a circle that borders the convex hull. The density is then the ratio of the number of pixels covered by the cell outline to the area (in pixels) of the convex hull.

Statistical analysis

A computerized statistics program (SigmaPlot Version 11.0, Systat Software Inc., San Jose, CA, USA) was used to evaluate the data. After checking the data for a normal distribution, the results were presented as mean values (SD). Between-group comparisons were performed with the one-way analysis of variance followed by the post-hoc Holm Sidak test (or the Kruskal-Wallis test for data without a normal distribution). A value of P < 0.05 was considered statistically significant.

Results

Argon reduces binding activity of STAT3 and NF-κB in SH-SY5Y cells exposed to rotenone

Exposure of human neuroblastoma cells (SH-SY5Y) to rotenone, a substance that blocks the mitochondrial respiratory chain and induces apoptosis, significantly increased STAT3 and NF-κB binding activity (P < 0.001; Figure 1A and B). Exposure to argon for another 2 hours caused a partial reduction in the STAT3 and NF-κB activity (P < 0.05 and P < 0.001; Figure 1A and B). Argon alone, in the absence of rotenone pretreatment, had no effect on STAT3 and NF-κB activity, while OxPAPC treatment reversed the argon effect in rotenone-treated cells (P < 0.05 and P < 0.001).
arguably decreased Nrf-2 transcriptional activity (expression of FasL (SH-SY5Y cells, exposure to rotenone increased the surface by fluorescence-activated cell sorting (FACS) analyses. In the possible effect of argon on FasL expression was evaluated.

Treatment of SH-SY5Y cells with rotenone significantly pretreatment, showed no impact on FasL DNA binding. OxPAPC treatment almost completely eliminated the effect of argon in rotenone-treated cells (P < 0.001; Figure 1C).

Argon decreases Nrf-2 DNA binding activity (C). Argon decreased Nrf-2 DNA binding activity. DNA binding enzyme-linked immunosorbent assay of Nrf-2 activity after rotenone treatment and argon (75%, v/v, 2 hours) fumigation. OxPAPC abolished Argon’s effect. Argon reduced FasL surface expression (D). Argon reduced FasL surface expression (fluorescence-activated cell sorting analysis). n = 6 in A–C, n = 8 in D. Data are expressed as the mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.001 (one-way analysis of variance with post-hoc Holm Sidak test). FasL: Fas ligand; NF-kB: nuclear factor kappa B; Nrf-2: nuclear factor erythroid 2-related factor 2; STAT3: signal transducer and activator of transcription 3.

Figure 1 | Argon reduces STAT3, NF-κB, and Nrf-2 DNA-binding activity and FasL surface expression in SH-SY5Y cells exposed to rotenone.

Argon reduces binding activity of Nrf-2 in SH-SY5Y cells exposed to rotenone.
Treatment of SH-SY5Y cells with rotenone significantly increased Nrf-2 binding activity (P < 0.001; Figure 1C), while subsequent treatment with argon mitigated rotenone effect and decreased Nrf-2 transcriptional activity (P < 0.001; Figure 1C). Argon alone, in the absence of rotenone pretreatment, showed no impact on Nrf-2 DNA binding. OxPAPC treatment almost completely eliminated the effect of argon in rotenone-treated cells (P < 0.001; Figure 1C).

Argon decreases FasL surface expression in SH-SY5Y cells exposed to rotenone.
The possible effect of argon on FasL expression was evaluated by fluorescence-activated cell sorting (FACS) analyses. In SH-SY5Y cells, exposure to rotenone increased the surface expression of FasL (P < 0.01; Figure 1D). Immediate argon treatment reduced the effect of rotenone and diminished FasL surface density, while argon alone, in the absence of rotenone pretreatment, showed no effect (P < 0.001; Figure 1D).

Argon differentially inhibits AP-1 proteins in SH-SY5Y cells exposed to rotenone.
Rotenone pretreatment of SH-SY5Y cells did not change the DNA binding activity of JunD and c-Fos (Figure 2A and B), but significantly increased binding of Fra-1 and c-Jun (P < 0.001; Figure 2C and D), indicating differential activation of AP-1 transcription proteins. However, the increase in FosB and c-Fos activity did not reach statistical significance (Figure 2E and F). Argon treatment alone, in the absence of rotenone pretreatment, had no impact on AP-1 protein binding (Figure 2A–F). However, OxPAPC treatment did not reverse the argon effect on DNA-binding activity for Fra-1 and c-Jun in rotenone-treated cells (Figure 2C and D).

Argon inhibits the in vivo release of inflammatory cytokines.
Retinal ischemia/reperfusion injury in the rats increased the retinal mRNA expression of IL-1a, IL-1β, IL-6, TNF-α, and iNOS compared to untreated control eyes (Figure 3A–E). A 2-hour exposure to argon immediately after reperfusion significantly decreased the ischemia/reperfusion injury-mediated pro-inflammatory cytokine expression significantly (P < 0.05 or P < 0.01; Figure 3A–E). Pretreatment with OxPAPC partly abolished argon’s effect on pro-inflammatory cytokine expression (P < 0.05 or P < 0.01; Figure 3A–E). Retinal ischemia/reperfusion injury had no effect on eNOS mRNA expression.

Argon attenuates in vivo microglial activation.
Immediately after ischemia/reperfusion injury, immunohistological staining with Iba-1 and the subsequent 3D reconstruction of the images revealed an increased number of microglial cell bodies. The cell bodies were also thickened and showed an asymmetric distribution of the extensions, indicative of microglial activation (Figure 4A and B). Immunoperoxidase labeling also showed the typical morphological changes. The density of the microglia increased after ischemia/reperfusion injury, but this change was significantly reduced by argon treatment (Figure 5A and B). OxPAP C abolished the effect of argon (Figure 4C and D; Figure 5A and B; P < 0.05 and P < 0.001).

Discussion
These in vitro and in vivo experiments validated the anti-inflammatory properties of argon. Argon treatment of human neuroblastoma cells injured by rotenone (1) reduced the...
binding activity of the transcription factors STAT3, NF-κB, and Nrf-2. (2) caused differential effects on the subunits of the transcription factor AP-1, and (3) diminished the surface expression of Fasl, a cytokine that induces apoptosis. In vivo treatment of rat retinas with argon reduced the activation of retinal microglial cells after ischemia/reperfusion injury, with subsequent suppression of retinal mRNA expression of inflammatory cytokines and iNOS. These effects could be reversed by inhibiting TLR2 and TLR4 signaling with OxPAPC.

Different neuronal injury models have shown that the destruction of neuronal tissue leads to a release of calcium and reactive oxygen radicals, which in turn stimulate the expression of different transcription factors, such as STAT3, NF-κB, and AP-1, to regulate the expression of proteins responsible for either cell survival or cell death (Chen et al., 2011). Inhibition of the expression of the transcription factor Nrf-2 has also been associated with neuroprotective mechanisms, so Nrf-2 has become a focus in studies regarding stroke and other neurological diseases (Jiang et al., 2017).

Transcription factors are involved in the development of cerebral inflammation and contribute to secondary neurological injury. Microglia, as the resident macrophages of the brain, are responsible for monitoring the microenvironment, so they would be expected to undergo alterations in transcription factors. Microglia undergo activation following neuronal damage, with a subsequent release of inflammatory cytokines. In the activated state, the number of microglia cells increase, with concomitant changes in their morphology. The cell body thickens and assumes an amoeboid shape, with an asymmetrical distribution of the processes (Chen and Trapp, 2016).

In previous experiments, we have shown that microglial activation is alleviated by argon treatment through effects on TLR2 and TLR4, which play important roles in neuroprotection (Ulbrich et al., 2015b, 2016). The present in vitro experiments in rotenone-treated human neuroblastoma cells confirmed that argon reduced the binding activity of TLR downstream transcription factors, such as STAT3, NF-κB, and Nrf-2, thereby preventing the neuronal cell death induced by rotenone inhibition of the mitochondrial respiratory chain. We further confirmed this effect on Toll-like receptors using OxPAPC to inhibit TLR2 and TLR4. OxPAPC alone was not neurotoxic, but OxPAPC treatment reversed the beneficial effects of argon on rotenone-treated cells. By contrast, the activity of transcription factor AP-1 was only partly inhibited and was not antagonized by OxPAPC, suggesting the involvement of still yet another mechanism.

Some studies have shown an association between neuronal markers and anti-apoptotic proteins, like microtubule-associated protein 2 and BCL-2, which would suggest a correlation with neuronal survival (Zhang et al., 2006; Xiong et al., 2011). By contrast, other studies have linked STAT3 activation to neuronal cell death (Dziennis and Alkayed, 2008). A recent study by Ito et al. (2019) on the influence of regulatory T cells on ischemic brain damage revealed that stroke induced STAT3 activation, but this activation was reduced by intraventricular injection of the neuroprotective amphiregulin released by regulatory T-cells. A correlation between neuroprotection and downregulation of NF-κB in association with Toll-like receptors has also been demonstrated in the several studies. For example, Hwang et
Our in vitro findings confirmed a contribution of some of the subunits of the AP-1 transcription factor in neuroprotection. JunD, C-Fos, FosB, and JunB showed no changes in response to rotenone, whereas Fra-1 and c-Jun were activated, and argon exposure significantly attenuated their DNA binding activity. Interestingly, OxPAPC could not reverse this effect of argon, suggesting the involvement of yet another mechanism that is independent of the toll-like receptors. The current literature indicates an involvement of proteins of the AP-1 group in the processes of neurodegeneration and neuroregeneration. In particular, c-Jun, a product of the mitogen-activated protein kinase JNK, is stimulated in apoptotic neuronal processes, whereas its inhibition is associated with neuroprotection, according to numerous studies (Herdegen and Waetzig, 2001). Experiments on a rat stroke model have confirmed the contribution of the JNK/c-Jun pathway to cerebral ischemia/reperfusion injury by demonstrating an increase in the apoptosis-inducing cytokine FasL, which is a central component of the JNK-pathway (Qi et al., 2010). Transcription factors play a crucial role in the activation of cerebral microglia, as indicated by strong induction by STAT3 (Planas et al., 1996) and pro-inflammatory pathways, such as NF-κB (Lee, 2013) and AP-1 (Hui et al., 2018), as well as involvement of the antioxidant regulator Nrf-2 (Vilhardt et al., 2017).

The activation of retinal microglia by ischemia/reperfusion was significantly reduced by argon inhalation. This neuroprotective effect of argon has now been demonstrated in a number of in vitro and in vivo models, but the mechanism of action has not yet been fully clarified. Our previous studies demonstrated an effect of argon on TLR2 and TLR4, which are receptors of the innate immune system, and subsequently on the mitogen-activated protein kinase ERK1/2, as well as a downregulation of the pro-inflammatory cytokine interleukin-8. In 2012, Fahlenkamp et al. reported that in vitro argon exposure increased ERK1/2 phosphorylation in the BV-2 microglial cell line. However, argon had no significant effect on ERK1/2 when the cells were pretreated with lipopolysaccharide; instead, argon treatment increased the release of the pro-inflammatory cytokine IL-1β. Zhuang et al. (2012) also demonstrated beneficial effects of argon after in vitro damage to cortical neuronal cells by oxygen glucose deprivation, as argon exposure attenuated cell death and reduced the expression of the pro-inflammatory cytokines TNF-α and IL-6. Fahlenkamp et al. (2014) showed that argon had no in vivo effect on the number of microglial cells in the rat during a temporary occlusion of the middle cerebral artery, though further ramifications on microglia were not investigated. However, expression analysis following argon exposure showed only a reduction in CD3 by argon and even an increase in the inflammatory cytokines IL-1β and IL-6. A recent study by Liu et al. (2019) suggested that argon suppression of microglial activation in a rat stroke model may be due to a promotion of M2 microglia/macrophage polarization, resulting in an anti-inflammatory macrophage phenotype.

In the present study, ischemia/reperfusion injury caused morphological alterations of retinal microglia in the form of thickened extensions, and it increased the numbers of retinal microglia cells. Argon exposure, in turn, reduced both the morphological changes and the density of retinal microglial cells, suggesting a reversal of activation. Moreover, argon reduced the release of iNOS, a marker of the pro-inflammatory microglial phenotype (Collmann et al., 2019).

Our in vivo examination of retinal microglia confirmed their activation by retinal ischemia/reperfusion damage due to elevated intraocular pressure. The increased number of retinal microglial cells detectable by immunoperoxidase staining was one sign of activation. The immunohistological staining with iba-1 also revealed morphological hallmarks of activation in the form of thickening of the cell bodies and an asymmetric distribution of the extensions. This microglial activation would be expected to increase the release of proinflammatory cytokines, such as IL-1β, IL-6, TNF-α, and iNOS.

Nrf-2 is an important element in the protection against neuronal inflammation, as it controls the release of antioxidant substances and influences the activation of microglia (Lee et al., 2005). Our study showed a significant reduction in Nrf-2 in response to argon exposure. Argon is viewed as a potent mediator of organ protection, as it upregulates the expression of a variety of antioxidant enzymes during oxidative stress. Our finding is contradictory to that of Zhao et al. (2016), who found an activation of Nrf-2 during argon-mediated neuroprotection after hypoxic-ischemic brain damage. The reason for this difference may be that Zhao et al. supplied argon over a period of 24 hours after oxygen-glucose withdrawal, and they processed and analyzed the cells after that time. By contrast, our protocol involved rotenone treatment for 4 hours, argon exposure for another 2 hours, and immediate processing of the cells. We speculate that the decisive factor may be the time interval and that Nrf-2 activation might only be detected at a later point in time after neuronal injury.

Figure 5  | Microglial activation in whole-mount specimen after immunoperoxidase labeling with CD11b (OX-42).
(A) Visualization of the morphology of retinal microglia by optical microscopy: Control eye, after ischemia/reperfusion injury (IRI), after IRI and argon post-conditioning, and after IRI treatment after application of the TLR2 and TLR4 inhibitor oxidized phospholipid 1-palmitoyl-2-archichonoyl-sino-glycerol-3-phosphorylcholine (OxPAPC, 1.5 mg/kg). Typical changes such as increase of microglial cell bodies, thickening and asymmetric distribution of extensions showing activation after ischemia/reperfusion, which is attenuated by argon (arrows). (B) Statistical analysis of microglial density: Argon significantly reduced the density increase due to IRI. Argon alone had no effect in the absence of IRI treatment. The previous application of OxPAPC prior to IRI neutralized the effect of argon. n = 6. Data are expressed as the mean ± SD. *P < 0.05, **P < 0.001 (one-way analysis of variance with post-hoc Holm Sidak test).
Conclusion
The results of this in vitro and in vivo study provide further details of the mechanism underlying argon neuroprotection. Argon appears to exert its neuroprotective effect by attenuating a number of transcription factors associated with toll-like receptors, thereby reducing microglial activation.
Argon is inexpensive and apparently has no adverse side effects, so its use in humans is feasible. Clinical studies should therefore be performed. In addition, growing evidence supports the use of argon to benefit other organ systems, such as the heart and kidneys.

Acknowledgments: The authors thank Heide Marniga from Department of Anesthesiology and Critical Care, Medical Center – University of Freiburg (medical-technical assistant) for the support. The authors also thank the staff of the Live Imaging Center Freiburg for the assistance collecting and evaluating images.

Author contributions: UG designed the study, is responsible for data analysis and evaluation, and wrote the manuscript. SSC conducted the experiments and helped with data analysis and evaluation. SSP conducted the experiments, helped with data analysis and evaluation, and edited the manuscript. HB helped with data analysis and evaluation, and was an advisor in the management of the study. FU designed the study, conducted the experiments, helped with data analysis and evaluation, and wrote the manuscript. All authors approved the final version of this manuscript.

Conflicts of interest: There are no competing interests.

Financial support: This work was financially supported by the Department of Anesthesiology and Critical Care, Medical Center - University of Freiburg, Germany. The article processing charge was funded by the Baden-Württemberg Ministry of Science, Research and Art and the University of Freiburg in the funding programme Open Access Publishing.

Institutional review board statement: All procedures involving animals conformed with the statement of The Association for Research in Vision and Ophthalmology for the use of animals in research in accordance with the Animal Research Reporting of In Vivo Experiments (ARRIVE) guidelines and concurred with the statement of The Association for Research in Vision and Ophthalmology for the use of animals in research in accordance with the institutional review board statement: All procedures involving animals were approved by the Committee of Animal Care of the University of Freiburg (approval No. 35-9185.81/G14-122) on October 19, 2012.

Copyright license agreement: The Copyright License Agreement has been signed by all authors before publication.

Data sharing statement: Datasets analyzed during the current study are available from the corresponding author on reasonable request.

Plagiarism check: Checked twice by iThenticate.

Peer review: Peer reviewed.

Open access statement: This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-Non-Commercial-ShareAlike 4.0 license, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new works are licensed under the identical terms.

References
Ahmad M, Dar NJ, Bhat ZS, Hussain A, Ali A, Liu H, Graham SH (2014) Inflammation in ischemic stroke: mechanisms, consequences and possible drug targets. CNS Neurol Drug Targets 13:1378-1396.
Bradford MM (1976) A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
Bruck A, Kurnaz P, Bleilevens C, Derwall M, Weis J, Noelle K, Rossaint R, Fries M (2014) Dose dependent neuroprotection of the noble gas argon after cardiac arrest in rats is not mediated by KATP-channel opening. Resuscitation 85:826-832.
Chen H, Yoshida H, Tam GS, Sun JG, Okami N, Sakata H, Maerz CM, Narashiman P, Gonders CE, Chan PH (2011) Oxidative stress in ischemic brain damage: mechanisms of cell death and potential molecular targets for neuroprotection. Antioxid Redox Signal 14:7147-7173.
Chen Z, Trapp BD (2016) Microglia and neuroprotection. J Neurochem 136 Suppl 1:1-10.
Collmann FM, Pijnenburg R, Hamzei-Taj S, Minassian A, Folz-Donahue K, Kukat C, Li S, Lee M (2013) Neurotransmitters and microglial-mediated neuroprotection in the use of argon to benefit other organ systems, such as the heart and kidneys. Crit Care 17:198.
Coburn M (2009) Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 13:1806.
Lee J, Li J, Johnson DA, Stein TD, Kraft AD, Calkins MJ, Jakel RJ, Johnson JA (2005) Nrf2, a multi-organ protector? FASEB J 19:106-1066.
Lee M (2013) Neurotransmitters and microglial-mediated neuroprotection. Curr Protein Pept Sci 14:21-32.
Li J, Nolte K, Broock G, Liebensted L, Weinandy A, Hollig A, Velderman M, Williuet M, Lauerkerki, Rossaint R, Conal I, Weiss F, Fahlenkamp A, Yang VM, Grottko O, Coburn M (2009) Argon: neuroprotection in in vitro models of cerebral ischemia and traumatic brain injury. Crit Care 13:1806.
Moretti A, Ferrar F, Villa RI (2015) Neuroprotection for ischemic stroke: current status and challenges. Pharmacol Ther 147:24-38.
Morrison H, Young K, Qureshi M, Rowe RK, Ushijita J (2017) Quantitative microglia analyses reveal diverse morphologic responses in the rat cortex after diffuse brain injury. Sci Rep 7:13211.
Mouhate A, Mehdi M (2016) Toll-like receptor 4-mediated immune stress in pregnant rats activates STAT3 in the fetal brain: role of interleukin-6. Pediat Res 79:781-787.
Nalampaduk KA, Smith NJ, Chelluboina B, Klopfenstein JD, Pinson DM, Wang DZ, Vigamortus R, Vermaall VK (2018) Prevention of the severity of post-ischemic inflammation and brain damage by simultaneous knockdown of Toll-like receptors 2 and 4. Neuroscience 373:82-92.
Ng KF, McCunliffe J, Gell AW (2011) Perioperative stroke in noncardiac, nonneurosurgical anesthesia. Anesth Analg 112:859-870.
Panis AM, Soriano MA, Berreuzo M, Justicia E, Estrada A, Pitarca S, Ferrer I (1996) Induction of Stat1 and Stat2, a signal transducer and transcription factor, in reactive microglia following focal cerebral ischemia. Eur J Neurosci 8:2612-2618.
Prazkowski P, Dabrowiak M, Ellert-Miklaszewska A, Kloss M, Miecikowski J, Kaza B, Ronowicz A, Hu F, Pietrokovski A, Kettenmann H, Komorowski J, Kaminiska B (2014) The small GTPases Trps Stat1 and 2 and their novel target Tjmi3 drive the expression of inflammatory genes in microglia. J Mol Med (Berl) 92:239-254.
Qi SH, Liu Y, Hao YV, Guan QH, Gu YH, Zhang J, Yan J, Han W, Zhang M, Zhang YQ (2010) Prevention of endothelial dysfunction and injury following decreased spherical ceramide in rats. Mol Sci 18:2347.
Ravichandran KS, Krause M, Loboda AW, Zilch T, Toepoel SC, Moomaw CR (2016) Arginase 2 expression is related to endothelial dysfunction in cerebral ischemia and reperfusion injury. Front Immunol 7:850.